- Home
- FEBO vs HSCS Comparison
FEBO vs HSCS Comparison
Compare FEBO & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FEBO | HSCS |
|---|---|---|
| Founded | 1993 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 7.5M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | FEBO | HSCS |
|---|---|---|
| Price | $0.74 | $2.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 5.6K | ★ 39.6K |
| Earning Date | 12-16-2025 | 12-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,110,653.00 | $6,250.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.58 | N/A |
| 52 Week Low | $0.61 | $2.01 |
| 52 Week High | $2.31 | $6.47 |
Technical Indicators
Market Signals| Indicator | FEBO | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 41.04 |
| Support Level | $0.65 | $2.36 |
| Resistance Level | $0.76 | $2.81 |
| Average True Range (ATR) | 0.04 | 0.26 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 65.38 | 49.12 |
Price Performance
Historical ComparisonAbout FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.